Document is current
Any future updates will be listed below
-
Authors
Adams, Emily https://orcid.org/0009-0006-9780-4006
Lavoie-Gagnon, Héloïse https://orcid.org/0000-0003-3974-5504
Islam, Farhana https://orcid.org/0000-0003-4800-0723
Humer, Michael
Mou, Benjamin https://orcid.org/0000-0002-5636-604X
Koulis, Theodora A.
Kim, David
Atrchian, Siavash https://orcid.org/0000-0002-7624-7128
-
Funding
Funding for this research was provided by:
Kelowna Association of Radiation Oncology
- License Information
-
More Information
Article History
Accepted: 7 April 2025
First Online: 18 April 2025
Declarations
:
: This study received harmonized research ethics board approval from UBC BC Cancer Research Ethics Board and Interior Health Research Ethics Board (study number H20 - 01958). We received a waiver of patient consent for our retrospective chart review and all study procedures were performed in accordance with the 1964 Helsinki Declaration.
: This study was granted a waiver of patient consent by the UBC BC Cancer and Interior Health Research Ethics Boards, so no patient consent is required for participation or publication. No identifying patient information is included in this article.
: Dr. Theodora Koulis has received honoraria from Merck for a speaker presentation and has attended and lectured at the Canadian Breast Cancer Symposium. Dr. Benjamin Mou has received honoraria from AstraZeneca, Bristol Myers Squibb and Amgen. The remaining authors have declared no financial or non-financial interests.
